Inflammx Therapeutics, Inc. Email Format

Biotechnology ResearchCalifornia, United States0-1 Employees

Inflammx Therapeutics, Inc. is a small biotechnology research company based in Tampa, Florida, focused on developing oral therapies aimed at modulating the NLRP3 inflammasome pathway implicated in autoinflammatory conditions. Its lead program, Xiflam, targets diseases driven by dysregulated inflammasome signaling, with clinical focus on Diabetic Macular Edema secondary to Diabetic Retinopathy and the early intermediate stage of Age-related Macular Degeneration. The company seeks to modify disease processes by normalizing abnormal connexin 43 hemichannel activity, which is linked to the release of signals that activate the NLRP3 inflammasome and downstream inflammatory cytokines. A recent Phase 2 trial reported positive data for Xiflam in DME, demonstrating patient dosing once daily for six months in a placebo-controlled setting. Inflammx operates in the biotechnology research sector and is positioned as a clinical-stage company developing targeted anti-inflammatory therapies, with a small team and a focus on advancing its oral inhibitor through further development.

Get verified Inflammx Therapeutics, Inc. emails free

Company overview Employee directory